Ajinomoto Co., Ltd.

Ryota Yoshimoto

Hiroshi Yamamoto

Tsuyoshi Kobayashi

Morikazu Kito

Masataka Shoji

Mitsuyo Nagano

Chikahiko Eguchi

Hideaki Kihara

Junji Hamuro

Akira Kamimura

Kozo Toyota

Hideki Domoto

Koichi Ishii

Naoyuki Fukuchi

Koji Mitsugi

Shingo Makino

Akiko Tanaka

Nobukazu Kashima

Yohko Kawai

Kiyoaki Watanabe

Harumi Arisaka

Yoshikatsu Koyama

Takashi Komiyama

Ken Hirose

Norman E Cameron

Yosikatsu Koyama

Akira Hirasawa

Yuichi Gyotoku

Yoshiaki Hanzawa

Hiroshi Sigematsu

A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.

Antithrombotic agent and anti-von willebrand factor monoclonal antibody

A compound 1-formyl-N-(2-(4-(5H-dibenzo&lsqb;a,d&rsqb;cyclohepten-5-ylidene)-1-piperidinyl)) ethyl isonipecotic acid amide or an analog thereof or a pharmaceutically acceptable salt thereof provides a therapeutic agent for treating a patient suffering from intermittent claudication.

Therapeutic agent for intermittent claudication

A thrombolytic drug containing cyproheptadine, a compound of the following formula or a salt thereof as the active ingredient is provided. This thrombolytic drug has a function of accelerating the release of a tissue plasminogen activator (t-PA), while exerting no effect on the release of type-1 plasminogen activator inhibitor (PAI-1) which deactivates t-PA or reducing the release thereof.

Thrombolytic drug

Disclosed is a pharmaceutical composition for use in the treatment of diabetic neuropathy, which comprises a piperidine derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an effective ingredient:

Pharmaceutical composition for use in the treatment of diabetic neuropathy

The present invention also relates to a method of using these novel materials, and other materials, to treat or prevent a disease caused by serotonin or a method of treating or preventing platelet aggregation. The compounds used are piperidine derivatives having the formula (I): ##STR1## wherein the various substituents are defined below.

Piperidine derivatives and anti-platelet agents containing the same

Antithrombotic agent and anti-von Willebrand factor monoclonal antibody

Peptide having anti-thrombus activity and method of producing the same

A piperidine compound of the formula (I): ##STR1## wherein A is a fused aromatic ring; R is hydrogen, chloro or methoxy; X is (CH.sub.2).sub.n, which may be substituted, in which n is 0 or an integer of 1 to 10, --CH.dbd.CH--, --C.dbd.C--, --O--, --S--, --NH--, --N(COCH.sub.3)--, --N(COOC.sub.2 H.sub.5)--, --N(CHO)--, --N(CH.sub.3)--, --CO--, --SO--, or --SO.sub.2 --; Y is --CH.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CH.sub.2 CO--, --O--, --S--, --NH--, --OCH.sub.2 --, --SCH.sub.2 --, --NHCH.sub.2 --, --CH(OH)CH.sub.2 -- or --CH(OH)CH(OH)--; and Q is substituted or unsubstituted n-hexyl, carboxypropyl, ethoxycarbonylpropyl, cyanopropyl, cyclohexyl, phenyl, indanyl, naphthyl, tetrahydronaphthyl, benzocycloheptyl, piperidinyl, tetrahydroisoquinolinyl, indolyl, pyrolyl, furyl, thienyl, thiazolyl, oxazolyl or N-methylpyrolyl, wherein any one or more of the --(CH.sub.2)-groups of the hexyl, carboxypropyl, ethoxycarbonylpropyl and cyanopropyl groups may be replaced by --CH.dbd.CH--, --C.dbd.C--, --O--, --S--, --NH--, --N(COCH.sub.3), --N(COC.sub.2 H.sub.5)--, --N(CHO)--, --N(CH.sub.3)--, --CO--, --SO-- or --SO.sub.2 --, and wherein one or more of the --(CH.sub.2)-groups in X and Q may be substituted by --(CH.sub.2).sub.4 -- or --(CH.sub.2).sub.5 -- thereby forming a ring structure.

Piperidine derivatives and hypotensives containing the same

An ethylamine derivative of formula (I): ##STR1## wherein A represents a carbon atom or a nitrogen atom;

Ethylamine derivatives and antihypertensives containing the same

A piperidine derivative of general formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein ##STR2## is any of several specified aromatic-containing groups; X is selected from one of several hetero atom-containing groups or C.sub.2 alkylene or a cyano-containing group; and Q is phenyl, cyclohexyl, piperidinyl, tetrahydropyranyl, pyridyl, pyrrolyl, N-methylpyrrolyl, thienyl, furyl, 1-hexyl, or cyano; from 1 to 3 hydrogen atoms in Q may be independently substituted by alkyl of from 1 to 3 carbon atoms, perfluoroalkyl of from 1 to 3 carbon atoms, acylamino of from 1 to 6 carbon atoms, perfluoroacylamino of from 1 to 3 carbon atoms, alkoxy of from 1 to 3 carbon atoms, alkanesulfonylamino of from 1 to 3 carbon atoms, perfluoroalkanesulfonylamino of from 1 to 3 carbon atoms, acetoxy of from 1 to 3 carbon atoms, aminocarbonyl, aminosulfonyl, fluoro, chloro, cyano, hydroxy, nitro, amino, imidazolylmethyl, cinnamoylamino, p-fluorobenzoyl, cyanomethyl, cyanoethyl, methoxyacetoxy, alkoxycarbonyl of from 1 to 3 carbon atoms; 1 is an integer of from 0 to 1; m is an integer of from 0 to 1; n is an integer of from 0 to 6. The derivatives are useful as antiarrhythmic agents.

Piperidine compounds and their use as antiarrhythmic agents

An immunopropylactic and immunotherapeutic agent comprising human interleukin 2 of human cellular origin is disclosed along with a method of producing the agent.

Immunoprophylactic and immunotherapeutic agents

Certain hybridomas preparing monoclonal antibodies to human interleukin-2 (IL-2) which do not cross react with rator mouse IL-2 are disclosed. The secreted monoclonal antibody can be used in immunoassays for human IL-2.

Hybridomas and monoclonal antibodies to human IL-2

Growing community of inventors

Kawasaki, Japan

Ryota Yoshimoto